Arbutus Biopharma announced plans for a modified Dutch auction tender offer to repurchase up to US$230 million of its common shares at a price between US$5.00 and US$5.75 per share in cash. The transaction is expected to commence around August 24, 2026, and expire on or about September 29, 2026, funded by the company's existing cash reserves. This initiative follows a March 2026 settlement with Moderna and aims to return financial proceeds to shareholders while the company continues legal enforcement of its lipid nanoparticle intellectual property rights against Pfizer and BioNTech. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious disease treatments.

Arbutus Biopharma reported a net loss of $5.1 million for Q2 2026, or $0.03 per share, compared to a net income of $2.5 million in the prior year period. Revenue declined to $1.0 million from $10.7 million due to the conclusion of a strategic partnership with Qilu. The company holds $92.6 million in cash and equivalents as of June 30, 2026. In July 2026, Arbutus received its share of approximately $178.4 million from a $950 million settlement with Moderna regarding patent infringement litigation. The company announced plans to return up to $230 million in capital to shareholders starting in Q3 2026 through potential share repurchases or tender offers. Additionally, Arbutus filed international lawsuits against Pfizer and BioNTech over lipid nanoparticle technology and received FDA Fast Track designation for its hepatitis B candidate imdusiran. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases.

Arbutus Biopharma received approximately $178 million on July 8, 2026, as its share of a $950 million noncontingent settlement payment from Moderna to resolve global patent infringement litigation. The company terminated its RSV Agreement with Genevant Sciences, receiving a $1.0 million termination fee. Arbutus filed three international lawsuits against Pfizer/BioNTech to enforce lipid nanoparticle technology patents. Additionally, the company announced plans to return up to $230 million to shareholders through share repurchases starting in Q3 2026, following an expected dividend from Genevant's parent. The Board approved litigation-related bonuses for CEO Lindsay Androski and CFO Tuan Nguyen. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases.